Bcr-Abl Modulator

L18I is a Bruton's tyrosine kinase (BTK) PROTAC degrader that targets wild-type and BTK^C481, and recruits the cereblon E3 ligase to mediate proteasomal degradation. L18I regulates the BCR, TLR, FcγR and NLRP3 inflammasome signaling pathways, inhibits the phosphorylation of PLCγ-2, ERK1/2 and p38, and reduces the levels of B cell activation markers CD25, CD69 and CD86. L18I downregulates the NF-κB, TNF and TLR signaling pathways, reduces the production of pro-inflammatory cytokines, and decreases immune cell infiltration and immune complex deposition. L18I inhibits the proliferation of BTK-expressing lymphoma cells, induces tumor regression in xenograft models, and exhibits synergistic activity when combined with inhibitors of SYK, PI3K or Lyn. L18I can be used in research related to lupus, diffuse alveolar hemorrhage and B-cell lymphoma.

Enzyme modulator-1 (example 205) is a potent enzyme modulator that modulates p38, bcr-ab1, and VEGFR. Enzyme modulator-1 can be used for the research of cancer, rheumatoid arthritis, retinopathies including diabetic retinal neuropathy and macular degeneration.